Advanced Prostate Cancer Clinical Content Integration
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T04:38:30.956Z Metadata:{"project":"Desktop","type":"feature","obs_id":65396}
obs/65396 · feature · 2026-05-04T04:38:30.956Z
Advanced Prostate Cancer Clinical Content Integration
Clinical presentation content implemented covering advanced prostate cancer care continuum from metastatic castration-sensitive (mCSPC) to castration-resistant (mCRPC) disease. Content synthesizes 2025-2026 regulatory and guideline updates including FDA darolutamide approval expansion, EAU/ESMO/AUA recommendations, and theranostic (Pluvicto) label changes. Trial evidence integrated includes ARANOTE darolutamide doublet data (rPFS median not reached vs 25.0 months), ARASENS triplet survival proof (4-year OS 62.7% vs 50.4%), and imaging considerations for PSMA PET vs conventional staging. Emergency management protocols structured as algorithm slide type for on-call resident decision support. Toxicity monitoring frameworks address longitudinal care beyond PSA response including cardiometabolic risk, CNS effects, and quality of life impacts.
Concepts: [“what-changed”,“how-it-works”]
Facts: [“Content covers mCSPC treatment intensification with ARANOTE trial (darolutamide + ADT, rPFS HR 0.54) and ARASENS trial (triplet OS HR 0.68)”,“Emergency management algorithm slide addresses cord compression, obstruction, pain crisis, and marrow suppression with intervention protocols”,“Timeline slide tracks FDA Pluvicto expansion (2025-03), guideline updates from ESMO 2026, EAU 2026, AUA 2026”,“ADT/ARSI toxicity management slide covers cardiometabolic, falls/cognition, drug interactions, and sexual health domains”,“Primary tumor radiotherapy and MDT content addresses PSMA PET imaging implications for oligometastatic disease”]
[← 回 Alfred Brain Hub]